Detalles de la búsqueda
1.
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: a case report within the experience of a single institution.
Anticancer Drugs
; 32(7): 755-757, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33661187
2.
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?
Anticancer Drugs
; 31(10): 1103-1105, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32826413
3.
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication.
Future Oncol
; 16(23): 1751-1766, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32539551
4.
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors.
JTO Clin Res Rep
; 4(9): 100563, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37745898
5.
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.
Target Oncol
; 17(1): 43-51, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35025076
6.
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies.
Immunotherapy
; 14(16): 1329-1340, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36382476
7.
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: the role of salvage chemo-immunotherapy combination.
Immunotherapy
; 13(5): 363-369, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33533279
8.
The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
Cancers (Basel)
; 12(11)2020 Oct 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-33114576
9.
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.
Crit Rev Oncol Hematol
; 156: 103119, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33053439
Resultados
1 -
9
de 9
1
Próxima >
>>